You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Claims for Patent: 11,344,512

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,344,512

Title:	Titration of tapentadol
Abstract:	The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.
Inventor(s):	Lange; Claudia (Wiesloh, DE), Rombout; Ferdinand (NL-Klimmen, NL)
Assignee:	Grunenthal GmbH (Aachen, DE)
Application Number:	16/439,135
Patent Claims:	1. A method of treating pain with a lower incidence of somnolence in a subject in need thereof, said method comprising orally administering to said subject: (i) a first dose of tapentadol of 50 mg.+-.5% or 100 mg.+-.5% twice daily (bid) during a first administration interval of at least 1-3 days; (ii) a second dose of tapentadol calculated by increasing said first dose by 50 mg to 100 mg.+-.5% or 150 mg.+-.5% twice daily (bid), respectively, during a second administration interval of at least 3-11 days following said first administration interval; and (iii) a third dose of tapentadol calculated by increasing said second dose by 50 mg to 150 mg.+-.5% or 200 mg.+-.5% twice daily (bid), respectively, during a third administration interval of at least 3-14 days following said second administration interval. 2. The method according to claim 1, which comprises orally administering to said subject: (i) a first dose of tapentadol of 50 mg.+-.5% twice daily (bid) during the first administration interval of at least 1-3 days; (ii) a second dose of tapentadol of 100 mg.+-.5% twice daily (bid) during the second administration interval of at least 3-11 days following said first administration interval; and (iii) a third dose of tapentadol of 150 mg.+-.5% twice daily (bid) during the third administration interval of at least 3-14 days following said second administration interval. 3. The method according to claim 1, which comprises orally administering to said subject: (i) a first dose of tapentadol of 100 mg.+-.5% twice daily (bid) during the first administration interval of at least 1-3 days; (ii) a second dose of tapentadol of 150 mg.+-.5% twice daily (bid) during the second administration interval of at least 3-11 days following said first administration interval; and (iii) a third dose of tapentadol of 200 mg.+-.5% twice daily (bid) during the third administration interval of at least 3-14 days following said second administration interval.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.